L
ow-density lipoprotein cholesterol (LDL-C) is a wellestablished risk factor for cardiovascular disease (CVD) and is the primary target of therapy (1) . Although LDL particles are the predominant circulating atherogenic lipoproteins, other triglyceride-rich lipoproteins, such as very-lowdensity and intermediate-density lipoproteins, have also been implicated in atherogenesis (2) . Apolipoprotein B100 reflects the total number of atherogenic lipoprotein particles-lowdensity, very-low-density, and intermediate-density-because all atherogenic particles carry an apolipoprotein B protein in a 1-to-1 fashion (2) . In contrast, high-density lipoprotein (HDL) particles do not carry apolipoprotein B100, but instead carry apolipoprotein A-I. Hence, apolipoprotein A-I reflects the potentially antiatherogenic HDL particles, although not in a 1-to-1 fashion, because each HDL particle may carry 1 or more apolipoprotein A-I molecules.
The inverse association between HDL cholesterol (HDL-C) levels and CVD is well-established (3) (4) (5) (6) (7) (8) (9) . However, whether this association remains across different levels of LDL-C is less well-studied, and the clinical significance of low HDL-C levels in patients with low LDL-C levels is under debate. Among men, the inverse association of HDL-C with CVD was consistent across a range of LDL-C values in several studies (4, 6, 10) . Among women, particularly healthy women, studies of the association of HDL-C across a range of LDL-C values are lacking (11) .
Likewise, whereas low concentrations of apolipoprotein A-I have been associated inversely with CVD (2), it is unclear whether apolipoprotein A-I is inversely associated with CVD across a range of LDL-C values. Whether apolipoprotein A-I or HDL-C levels are inversely associated with CVD when concentrations of apolipoprotein B100 are low is also unclear.
Therefore, we examined the associations of HDL-C and apolipoprotein A-I with incident CVD, including coronary and stroke events, in apparently healthy women across a range of concentrations for LDL-C and apolipoprotein B100. Furthermore, because clinicians encounter women with very high HDL-C concentrations and it is unknown whether these women are more protected against CVD, our secondary aim was to determine whether very elevated HDL-C levels occurring spontaneously in these women provided additional protection.
METHODS

Study Population
Study participants were drawn from the Women's Health Study, a completed randomized, double-blind, placebo-controlled trial of low-dose aspirin and vitamin E in the primary prevention of CVD and cancer in women (12) (13) (14) . Participants were apparently healthy female health care professionals, aged 45 years or older, who were free of self-reported CVD and cancer at study entry (1992) (1993) (1994) (1995) . At the time of enrollment, women gave written informed consent and completed questionnaires on demographic and anthropometric characteristics, medical history, and lifestyle factors. They were also asked to provide a baseline blood sample; 28 345 women did so, and of these, 28 023 had baseline lipid measurements. We excluded 275 women with missing values for any of the lipid or apolipoprotein measurements and 887 who were receiving lipid-lowering medication, resulting in 26 861 women for analysis (Figure) . The study was approved by the institutional review board of Brigham and Women's Hospital, Boston, Massachusetts.
Laboratory Measurements
Ethylenediamine tetraacetic acid-treated blood samples were obtained at the time of enrollment and stored in vapor-phase liquid nitrogen (Ϫ170°C). In a laboratory certified by the National Heart, Lung, and Blood Institute/ Centers for Disease Control and Prevention Lipid Standardization program, baseline samples were thawed and analyzed for standard lipids. Direct determination of concentrations of HDL-C and LDL-C were simultaneously performed on the Hitachi 917 analyzer (Roche Diagnostics, Indianapolis, Indiana) by using reagents and calibrators from Roche Diagnostics. The LDL-C values were determined by using a homogenous direct method from Roche Diagnostics. The HDL-C values were determined by using a direct enzymatic colorimetric assay. Apolipoproteins A-I and B100 were measured by using immunoturbidimetric assays (DiaSorin, Stillwater, Minnesota). Coefficients of variation were less than 3% for apolipoprotein A-I, LDL-C, and HDL-C and less than 5% for apolipoprotein B100.
Ascertainment of CVD Events
The primary outcomes of interest were a composite end point of incident total CVD (nonfatal myocardial infarction, nonfatal stroke, percutaneous coronary intervention, coronary artery bypass grafting, or cardiovascular death), incident coronary disease (nonfatal myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, or coronary death), and incident stroke. Every 6 months for the first year and annually thereafter, women received follow-up questionnaires about the occurrence of end points. Nonfatal end points were based on self-reports from follow-up questionnaires, letters, or telephone calls. For each reported CVD end point, we requested permission from the participant to examine the relevant medical records. A copy of the death certificate and additional records were requested as needed. Selfreported cases were classified as confirmed if they were reviewed by the end points committee and fulfilled the necessary confirmation criteria, and only confirmed events were included in analyses, as described elsewhere (14) . The confirmatory rates among the records reviewed are 98.5% for CVD death, 95.8% for myocardial infarction, 97.8% for coronary artery bypass grafting, 94.9% for percutaneous coronary intervention, and 93.4% for stroke.
Statistical Analysis
Statistical analyses were done by using STATA software, version 10.1 (StataCorp, College Station, Texas). We divided HDL-C and apolipoprotein A-I levels into quin-
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tiles based on their distribution among women who were not using postmenopausal hormones, following guidelines from the Department of Health and Human Services for lipid standardization, and these quintile cut points were then applied to the rest of the cohort (15) . Survival analysis was performed by using incidence rates and Cox proportional hazards regression models to adjust for covariates. The P value for linear trend was obtained by using the median value for each quintile.
To compare our results with prior studies, we first adjusted for age and then further adjusted for race, randomized treatment assignment, smoking status, systolic blood pressure, antihypertensive medication use, fasting status, alcohol use, and family history of premature coronary disease (model 1); we then added postmenopausal status, postmenopausal hormone use, body mass index, exercise, diabetes mellitus, high-sensitivity C-reactive protein level, and triglyceride level (model 2). Models that did not stratify by LDL-C levels also included adjustment for LDL-C. Correlations between HDL-C or apolipoprotein A-I values and model covariates were low to moderate (Spearman r Յ|0.4|). Colinearity of covariates was examined by comparing unadjusted with adjusted models, and no evidence of colinearity was detected.
We then evaluated the associations of HDL-C and apolipoprotein A-I with incident events by dividing participants by tertile cut points for LDL-C or apolipoprotein B100 levels, which were chosen to allow comparison of associations within similar strata of LDL-C and apolipoprotein B100.
Finally, we stratified according to baseline HDL-C or apolipoprotein A-I deciles among non-hormone users to examine naturally occurring, extreme elevations in HDL-C and apolipoprotein A-I levels. We determined the associations and characteristics of women with extreme elevation of HDL-C or apolipoprotein A-I, defined as either the top decile or the top 3% of concentrations. All reported P values were 2-tailed, and values less than 0.05 were considered significant.
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RESULTS
At baseline (Table 1) , the study participants were middle-aged women with a mean HDL-C concentration of 1.40 mmol/L (SD, 0.39) (54 mg/dL [SD, 15] ) and a mean apolipoprotein A-I concentration of 1.51 g/L (SD, 26). As expected, the baseline prevalence of cardiovascular risk factors was inversely associated with HDL-C values. Similar results were found when these baseline risk factors were examined across quintiles of apolipoprotein A-I (data not shown).
Levels of HDL-C and Apolipoprotein A-I and Incident CVD Events
During a mean follow-up of 11.1 years (SD, 1.3), 929 incident total CVD events occurred; of these, 602 were coronary (myocardial infarction, coronary revascularization, or coronary death) and 319 were strokes. The inci- CHD ϭ coronary heart disease; CVD ϭ cardiovascular disease.
Original Research HDL Cholesterol and Cardiovascular Events in Women dent CVD and coronary event rates increased linearly with lower concentrations of HDL-C or apolipoprotein A-I (P for linear trend Ͻ 0.001) ( Table 2) , whereas only the lowest quintile of HDL-C had an increased risk for stroke. After adjustment for known cardiovascular risk factors (models 1 and 2), HDL-C level remained inversely associated with CVD and coronary events. Adjusted coronary event hazard ratios (HRs) for decreasing quintiles of HDL-C were 1.00 (reference), Inverse associations were also noted between HDL-C and apolipoprotein A-I values and CVD and coronary events within subgroups of women stratified by age, race, hypertension, smoking status, diabetes, hormone use, and body mass index (data not shown).
In multivariable analyses, no associations were noted between HDL-C or apolipoprotein A-I values and stroke.
Associations Across Strata of LDL-C
Because the associations of HDL-C and apolipoprotein A-I levels with CVD were driven by coronary events and not stroke, we performed stratified analyses to examine coronary events across LDL-C levels. As shown in Table 3 , the lowest event rates (0.62 per 1000 person-years) were seen among women with values in the top quintile of HDL-C (Ͼ1.60 mmol/L [Ͼ61.6 mg/dL]) and concomitantly low LDL-C values (Ͻ2.80 mmol/L [Ͻ108 mg/dL]). After adjustment for other risk factors, the inverse association of HDL-C remained statistically significant for coronary events across a range LDL-C values, even among women with low LDL-C concentrations; the adjusted coronary HRs in model 2 for decreasing quintiles of HDL-C were 1.00 (reference), 1.78 (CI, 0.77 to 4.08), 0.98 (CI, 0.33 to 2.84), 2.30 (CI, 0.99 to 5.34), and 2.71 (CI, 1.14 to 6.46) (P for linear trend ϭ 0.031).
Weaker inverse associations were found between apolipoprotein A-I level and coronary events (Appendix Table, available at www.annals.org), particularly among women with LDL-C levels less than 3.50 mmol/L (Ͻ135 mg/dL). Furthermore, no association was observed between HDL-C or apolipoprotein A-I levels and stroke across strata of LDL-C after multivariable adjustment (data not shown). 
Associations Across Strata of Apolipoprotein B100
Associations were noted for HDL-C or apolipoprotein A-I only among women with apolipoprotein B100 levels of 0.90 g/L or greater ( Table 4 and Appendix Table) -that is, in the presence of atherogenic particles that include both LDL and the triglyceride-rich lipoprotein particles (for the interaction of apolipoprotein B100 by HDL-C, P ϭ 0.28; for apolipoprotein B100 by apolipoprotein A-I, P ϭ 0.21). In multivariable analysis, no association was observed between HDL-C or apolipoprotein A-I values and stroke across strata of apolipoprotein B100.
Sensitivity Analyses
We performed sensitivity analyses to assess the extent to which an unmeasured covariate might explain the results (16) . An unobserved dichotomous covariate that is almost perfectly correlated with coronary events would have to increase the odds of having a low (below median) HDL-C 
Extreme Elevation of HDL-C and Incident CVD Events
To examine the effect of naturally occurring elevations among non-hormone users, we stratified participants according to deciles of HDL-C or apolipoprotein A-I. Inverse associations with coronary events seemed to plateau above an HDL-C concentration of approximately 1.48 mmol/L (57 mg/dL) (Appendix Figure, available The inverse association with coronary disease persisted among women with HDL-C levels of 2.07 mmol/L or greater (Ն80 mg/dL) (approximately the top 3% of women), with an age-adjusted HR of 0.20 (CI, 0.09 to 0.43) compared with women in the bottom decile. Similarly, for women in the top 3% of apolipoprotein A-I values (Ն1.9 g/L), the age-adjusted HR was 0.35 (CI, 0.18 to 0.66).
DISCUSSION
In this prospective study of apparently healthy middleaged women, baseline HDL-C level was consistently and inversely associated with incident coronary and CVD events independent of other risk factors, whereas apolipoprotein A-I showed weaker associations. Consistent inverse associations were found for HDL-C across a range of LDL-C values, including among women with low LDL-C levels. Among women with decreased total atherogenic particle burden (as measured by an apolipoprotein B100 CHD ϭ coronary heart disease; HDL-C ϭ high-density lipoprotein cholesterol; HR ϭ hazard ratio; LDL-C ϭ low-density lipoprotein cholesterol; PY ϭ person-year. * "CHD events" comprise myocardial infarction, coronary revascularization, and deaths from CHD. Beginning at puberty and continuing throughout their lifetime, women typically have higher HDL-C and apolipoprotein A-I concentrations than men (17) . The current study adds to the literature in finding a statistically significant inverse association for HDL-C with coronary events (but not stroke) among women with different levels of LDL-C, including those with naturally occurring low LDL-C levels. The Framingham study was the first to report on the inverse association of HDL-C with coronary events, with each 1% risk in HDL-C associated with an approximately 2% decrease in coronary events (3, 4) . Among men, this inverse association was consistent across a range of LDL-C values, including those with low LDL-C (4), but the results were not reported by LDL-C levels among women in the Framingham study. Subsequent studies confirmed these findings in men (6, 10, 18) but did not include women.
Although data on the association of HDL-C level with CVD across LDL-C values in women are scarce, a study from the Lipid Research Clinics found that the inverse association for HDL-C levels greater than 1.30 mmol/L (Ͼ50 mg/dL) with CVD mortality persisted in women with LDL-C levels less than 3.37 mmol/L (Ͻ130 mg/dL) (11) . In that study, which had a population enriched with lipoprotein abnormalities but evaluated only CVD mortality outcomes, HDL-C was not examined at lower LDL-C cut points and comparison data for apolipoproteins were unavailable. Our study extends the results of prior studies by analyzing the associations at a range of concentrations, including at lower LDL-C levels among apparently healthy women; including a detailed analysis of apolipoproteins A-I and B100; and examining coronary and stroke outcomes separately.
Less is known about apolipoprotein A-I and CVD in individuals with naturally low LDL-C or apolipoprotein B100 levels (19). In a meta-analysis of 21 studies, apolipoprotein A-I level was inversely associated with CVD, with approximately 60% higher risk for the bottom tertile (20) . We found that the inverse association of apolipoprotein A-I with CVD in women became attenuated and no longer statistically significant when the LDL-C level was low. In comparison, the association of HDL-C remained statistically significant.
We can only speculate on why HDL-C lost its association with CVD at lower concentrations of total atherogenic particles as measured by low apolipoprotein B100 concentrations. The number of coronary events among women with LDL-C levels less than 2.80 mmol/L (Ͻ108 mg/dL) was lower than that among women with an apolipoprotein B100 level less than 0.90 g/L (117 vs. 78, re- Original Research HDL Cholesterol and Cardiovascular Events in Women spectively). Compared with LDL-C, apolipoprotein B100 is more closely related to insulin resistance and other features of the metabolic syndrome (21) , such that the predictive value may be lower for HDL-C, a key component of insulin resistance and the metabolic syndrome, when apolipoprotein B100 levels are already naturally low. It is also possible that HDL-C, which is essential for reverse cholesterol transport to the liver, is more "cardioprotective" in the presence of increased concentrations of total atherogenic particles. Finally, we found that women with very high HDL-C concentrations were not immune to CVD. However, compared with women who had low HDL-C concentrations, they were at lower risk for incident CVD and had first CVD events at older ages. In contrast to a study that found increased risk for CVD when HDL-C levels were greater than 2.07 mmol/L (Ͼ80 mg/dL) (22), we found reduced risk at the highest levels of HDL-C in these healthy women. Furthermore, women with very high HDL-C who experienced events had concomitantly higher prevalence of other risk factors that may have overridden the beneficial effects of a high HDL-C value. The HDL-C level can be increased naturally (by as much as 20% to 30%) through nonpharmacologic modifications that include weight loss, aerobic exercise, tobacco cessation, and healthy dietary choices (23). Compared with men, women may sustain even greater HDL-C increases by participating in regular exercise programs for extended periods (24) . Although current guidelines are inconsistent on whether HDL-C should be a primary, secondary, or tertiary target of therapy, they all recommend adoption of healthier lifestyle when the HDL-C level is low (1, 25, 26) .
Our study has limitations. First, it is unclear whether our findings in this population of low-risk primary prevention women are applicable to higher-risk individuals, such as those in secondary prevention settings or those receiving lipid-lowering therapy. Second, fewer events occurred among women in the lowest apolipoprotein B100 stratum, and we cannot exclude that HDL-C would be inversely associated with CVD in those with low apolipoprotein B100 if there were more events. Third, only a single measurement of lipids and apolipoproteins was available at baseline; we therefore could not examine the value of repeated measurements of these biomarkers. Fourth, our study population was limited to health care professionals who were mostly white. Finally, we cannot rule out unmeasurable or residual confounding due to measurement error in the model variables or to unmeasured variables.
Our study also has strengths, including the reliable measurement of HDL-C, LDL-C, and apolipoproteins with high accuracy in a core laboratory. We had wellcharacterized risk factor profiles for the participants, allowing us to control for potential confounding for both lipid and nonlipid variables. Finally, the study had a large sample and long duration of follow-up, and coronary, stroke, and total incident CVD events were ascertained.
In conclusion, in this prospective study of women, baseline concentrations of HDL-C and apolipoprotein A-I were associated with incident coronary and CVD events independent of other risk factors. In contrast, no associations were observed between these values and stroke after adjustment for other risk factors. Consistent inverse associations were found for HDL-C level and CVD across a range of LDL-C values, including low LDL-C levels. Among women with low total atherogenic particle burden (apolipoprotein B100 level Ͻ0.90 g/L), few events occurred and no associations were seen for HDL-C or apolipoprotein A-I.
MANUSCRIPT PROCESSING AND TURNAROUND
Annals sends about half of submitted manuscripts for peer review and publishes about 10% of submitted material. The 2010 processing and notification turnaround time for manuscripts that were rejected without external peer review was within 1 week for more than 95% of submitted manuscripts. The processing and notification turnaround time for manuscripts that were received and rejected after external peer review was within 4 weeks for 50% and within 8 weeks for 98%.
Original Research HDL Cholesterol and Cardiovascular Events in Women
